Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings

Derek James Sloan*, Joseph M. Lewis

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

27 Citations (Scopus)

Abstract

Despite overall progress in global TB control, the rising burden ofmultidrug-resistant TB (MDR-TB) threatens to undermine efforts to end theworldwide epidemic. Of the 27 countries classified as high burden for MDR-TB, 17 are in 'low' or 'low-middle' income countries. Shorter, all oral and less toxic multidrug combinations are required to improve treatment outcomes in these settings. Suitability for safe co-administration with HIV drugs is also desirable. A range of strategies and several new drugs (including bedaquiline, delamanid and linezolid) are currently undergoing advanced clinical evaluations to define their roles in achieving these aims. However, several clinical questions and logistical challenges need to be overcome before these new MDR-TB treatments fulfil their potential.

Original languageEnglish
Article numbertrv107
Pages (from-to)163-172
Number of pages10
JournalTransactions of the Royal Society of Tropical Medicine and Hygiene
Volume110
Issue number3
DOIs
Publication statusPublished - Mar 2016

Keywords

  • Bedaquiline
  • Delamanid
  • Extensively drug-resistant
  • Linezolid
  • Multidrug-resistant
  • Tuberculosis

Fingerprint

Dive into the research topics of 'Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings'. Together they form a unique fingerprint.

Cite this